|Medical news of Remedium.ru portal is the most update information on pharmaceutical and medical equipment market|
Home / News
Pharm-Olam International Opens St. Petersburg Office
Pharm-Olam International Ltd. (POI) and MB Quest (MBQ), a member of the POI Group, announce the opening of a third Russian office in St. Petersburg. POI is a multi-national full service CRO to pharmaceutical and biotech industries.
"With offices in Moscow, Novosibirsk, and now St. Petersburg we can offer sponsors cost effective coverage in the three most populated areas in Russia", said Eugene Barg, President of MBQ. “We have conducted clinical research in Russia since 1997, and had previously covered sites in St. Petersburg with regional employees. Because of the concentration of state-approved sites for research and the continued interest from sponsors it made sense to establish a permanent office there. We have highly qualified clinical teams throughout Russia and the majority of our staff have medical degrees and PhDs and many of them are specialists.”
The St. Petersburg office location provides convenient access to several therapeutic hospitals in the second largest metro area in Russia and expects to have 20 clinical staff by Q4 2008. With the addition of St. Petersburg, the Pharm-Olam International Group now has 25 offices worldwide to assist sponsors in Phase I to Phase IV research.
MBQ which operates in Russia, Ukraine, Georgia, and Belarus is a member of the POI Group. MBQ is also a founding member of the Association of Clinical Trial Organizations in Russia (ACTO). The ACTO’s mission is to assist in the development of clinical trials in Russia by improving the quality and protecting the rights and interests all parties involved.
Prior to the formation of the ACTO, several companies in Russia, including MBQ, played an important role in successfully resolving a biological sample export ban that occurred in May 2007 within two weeks of its announcement.
Based on this successful collaboration, the ACTO was established and MBQ’s medical director currently serves as a co-chairman. The number of internationally sponsored clinical trials in Russia grew from just over 100 in 2000 to over 300 in 2007.
The U.S. FDA began investigator inspections in Russia in 1995 and has conducted 36 investigations since February 2007. While there are fewer inspections to compare Russia to domestic U.S. inspections, the outcomes indicate that Russia has comparable or better compliance.
For further information about conducting trials with Pharm-Olam please contact Iain Gordon, Vice President of Business Development, at firstname.lastname@example.org About Pharm-Olam International Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, POI focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.